In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...

OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...

In the March 18 episode of 'Denise Richards & Her Wild Things,' Sami Sheen gets emotional during a doctor's visit with mom ...

A new study published in the European Archives of Oto-Rhino-Laryngology revealed that serum 25(OH)D deficiency is an ...

Not only adults, nasal polyps can also occur in children. Polyps are an inflammation of the nasal membranes and sinuses that ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...

Application of the ACE-Star Evidence-Based Nursing Model Combined with Voice Training in Voice Rehabilitation after Vocal Cord Polyp Surgery ...

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...